Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years

Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Infect Dis
Главные авторы: Diallo, Aldiouma, Sow, Samba O., Idoko, Olubukola T., Hirve, Siddhivinayak, Findlow, Helen, Preziosi, Marie-Pierre, Elie, Cheryl, Kulkarni, Prasad S., Parulekar, Varsha, Diarra, Bou, Cheick Haidara, Fadima, Diallo, Fatoumata, Tapia, Milagritos, Akinsola, Adebayo K., Adegbola, Richard A., Bavdekar, Ashish, Juvekar, Sanjay, Chaumont, Julie, Martellet, Lionel, Marchetti, Elisa, LaForce, Marc F., Plikaytis, Brian D., Enwere, Godwin C., Tang, Yuxiao, Borrow, Ray, Carlone, George, Viviani, Simonetta
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2015
Предметы:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639491/
https://ncbi.nlm.nih.gov/pubmed/26553684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ518
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы